Verdonk C A, Rizza R A, Nelson R L, Go V L, Gerich J E, Service F J
J Clin Invest. 1980 May;65(5):1119-25. doi: 10.1172/JCI109765.
Gastric inhibitory polypeptide (GIP) is considered to be the principal mediator of the enteroinsular axis. A glucose-insulin clamp technique was used to study the effects of differing blood glucose levels on the insulinotropic and glucagonotropic actions of fat-stimulated GIP in seven healthy subjects, as well as the effect of physiologic hyperinsulinemia on GIP secretion. Blood glucose levels were clamped for 4 h at 43+/-2 mg/dl (hypoglycemic clamp), 88+/-1 mg/dl (euglycemic clamp), and 141+/-2 mg/dl (hyperglycemic clamp) in the presence of a constant insulin infusion (100 m U/kg per h). Under hypoglycemic clamp conditions there was no increase in C-peptide nor glucagon after Lipomul ingestion, despite an increase of GIP of 51.7+/-8.7 ng/ml per 120 min. Under euglycemic clamp conditions, small and inconsistent increases in C-peptide and glucagon were observed after fat ingestion and a concomitant increase of GIP of 35.2+/-9.4 ng/ml per 120 min. Under hyperglycemic clamp conditions after fat ingestion and a GIP increase of 24.0+/-5.7 ng/ml per 120 min, C-peptide increased from 6.4+/-5 ng/ml to 11.0+/-1.1 ng/ml (P < 0.01) but glucagon did not change. These findings confirm that in healthy man GIP exerts its insulinotropic properties only under hyperglycemic conditions and indicate that GIP is not glucagonotropic. Under euglycemic clamp conditions (plasma glucose, 89+/-1 mg/dl) and physiologic hyperinsulinemia (serum immunoreactive insulin, 137+/-3 muU/ml) GIP responses to fat ingestion (39.7+/-9.8 ng/ml per 120 min) were not different from the GIP responses to fat ingestion in the absence of hyperinsulinemia (39.7+/-11.1 ng/ml per 120 min). Therefore, insulin under normoglycemic conditions does not exert an inhibitory effect on fat-stimulated GIP secretion. The higher GIP response to oral fat in the hypoglycemic clamp, and the lower GIP response in the hyperglycemic clamp compared to the response in the euglycemic clamp suggests an effect of glycemia itself on GIP secretion in the presence of hyperinsulinemia.
胃抑制多肽(GIP)被认为是肠胰岛轴的主要介质。采用葡萄糖 - 胰岛素钳夹技术,研究了七种健康受试者中不同血糖水平对脂肪刺激的GIP促胰岛素和促胰高血糖素作用的影响,以及生理性高胰岛素血症对GIP分泌的影响。在持续输注胰岛素(100 mU/kg每小时)的情况下,将血糖水平分别钳夹在43±2 mg/dl(低血糖钳夹)、88±1 mg/dl(正常血糖钳夹)和141±2 mg/dl(高血糖钳夹)4小时。在低血糖钳夹条件下,尽管每120分钟GIP增加51.7±8.7 ng/ml,但摄入Lipomul后C肽和胰高血糖素均未增加。在正常血糖钳夹条件下,摄入脂肪后观察到C肽和胰高血糖素出现小幅度且不一致的增加,同时GIP每120分钟增加35.2±9.4 ng/ml。在高血糖钳夹条件下,摄入脂肪后GIP每120分钟增加24.0±5.7 ng/ml,C肽从6.4±5 ng/ml增加到11.0±1.1 ng/ml(P<0.01),但胰高血糖素未改变。这些发现证实,在健康男性中,GIP仅在高血糖条件下发挥其促胰岛素特性,并表明GIP不具有促胰高血糖素作用。在正常血糖钳夹条件下(血浆葡萄糖,89±1 mg/dl)和生理性高胰岛素血症(血清免疫反应性胰岛素,137±3 μU/ml)时,GIP对脂肪摄入的反应(每120分钟39.7±9.8 ng/ml)与无高胰岛素血症时GIP对脂肪摄入的反应(每120分钟39.7±11.1 ng/ml)无差异。因此,正常血糖条件下的胰岛素对脂肪刺激的GIP分泌不产生抑制作用。与正常血糖钳夹相比,低血糖钳夹时GIP对口服脂肪的反应更高,高血糖钳夹时GIP反应更低,这表明在高胰岛素血症存在的情况下,血糖本身对GIP分泌有影响。